苯磺酸瑞马唑仑用于肥胖患者无痛胃肠镜检查术中的安全性及有效性研究  

Safety and efficacy of remazolam benzoate for painless gastroenteroscopy in obese patients

作　　者：周夏匀 于鹏威 吴琴丽 魏青 高特生[1] ZHOU Xiayun;YU Pengwei;WU Qinli(Department of Anesthesiology,Jiaxing Hospital of Traditional Chinese Medicine,Jiaxing 314000,China)

机构地区：[1]嘉兴市中医医院麻醉科,浙江嘉兴314000

出　　处：《全科医学临床与教育》2025年第4期324-327,共4页Clinical Education of General Practice

基　　金：嘉兴市科技计划项目(2022AD30107)。

摘　　要：目的探究苯磺酸瑞马唑仑用于肥胖患者无痛胃肠镜检查中的安全性及有效性。方法选择行无痛胃肠镜检查的患者62例,按随机数字表法分成两组:实验组和对照组,各31例。实验组予以静脉注射布托啡诺0.3 mg,2 min后静脉注射苯磺酸瑞马唑仑0.15 mg/kg;对照组予以静脉注射布托啡诺0.3 mg和丙泊酚1.5 mg/kg。比较两组患者麻醉给药前(T_(0))、胃镜过喉部(T_(1))、肠镜开始时(T_(2))、肠镜过肝区(T_(3))、唤醒时(T4)的生命体征;比较两组的起效时间、苏醒时间,以及术中、术后不良反应发生情况。结果T_(2)、T_(3)时,对照组患者的心率(HR)、平均动脉压(MAP)、血氧饱和度(SpO_(2))值均低于T_(0)(t分别=3.43、3.59、2.45、1.98、11.90、9.71,P均<0.05),实验组患者的HR、MAP、SpO_(2)与T_(0)比较,差异均无统计学意义(t分别=1.46、1.25、1.67、1.59、1.67、1.31,P均>0.05)。实验组患者在T_(2)、T_(3)时HR、SpO_(2)明显高于对照组(t分别=3.15、3.50、8.44、7.53,P均<0.05)。实验组患者的起效时间长于对照组、苏醒时间短于对照组,差异均有统计学意义(t分别=3.61、-4.08,P均<0.05)。实验组患者的注射痛、心动过缓、呼吸抑制、头晕、药物补救发生率均低于对照组,差异均有统计学意义(χ^(2)分别=41.89、9.18、5.42、5.16、5.44,P均<0.05)。结论苯磺酸瑞马唑仑可安全用于肥胖患者无痛胃肠镜检查术,具有无注射痛、不良反应率低,对呼吸、血流动力学影响小等优势。Objective To explore the safety and efficacy of remazolam besylate for painless gastroenteroscopy in obese patients.Methods A total of 62 patients who underwent painless gastroscopy were randomly divided into experimental group and control group according to random number table method,31 cases in each.The experimental group was given butorphanol 0.3 mg intravenously and remazolam 0.15 mg/kg intravenously 2 minutes later.The control group was given butorphanol 0.3 mg and propofol 1.5 mg/kg intravenously.The vital signs of the two groups were compared before anesthesia administration(T_(0)),after gastroscopy through larynx(T_(1)),at the beginning of colonoscopy(T_(2)),after colonoscopy through liver area(T_(3)),and after awakening(T4).The onset time,recovery time,and the occurrence of intraoperative and postoperative adverse reactions were compared between the two groups.Results At T_(2) and T_(3),the values of HR,MAP and SpO_(2) in the control group were lower than those of T_(0)(t=3.43,3.59,2.45,1.98,11.90,9.71,P<0.05),and there was no significant difference in the values of HR,MAP and SpO_(2) in the experimental group when compared with those of T_(0)(t=1.46,1.25,1.67,1.59,1.67,1.31,P>0.05).At T_(2) and T_(3),HR and SpO_(2) in the experimental group were significantly higher than those in the control group(t=3.15,3.50,8.44,7.53,P<0.05).The onset time of the experimental group was longer than that of the control group,and the recovery time was shorter than that of the control group,with statistical significance(t=3.61,-4.08,P<0.05).The incidence of injection pain,bradycardia,respiratory depression,dizziness and drug remedy in the experimental group were lower than those in the control group,and the differences were statistically significant(χ^(2)=41.89,9.18,5.42,5.16,5.44,P<0.05).Conclusion Remazolam benzosulfonate can be safely used for painless gastroenteroscopy in obese patients,and has the advantages of no injection pain,low adverse reaction rate,and little influence on respiration and hemodynamics.

关 键 词：瑞马唑仑 丙泊酚 布托啡诺 无痛胃肠镜 

分 类 号：R614[医药卫生—麻醉学]